NASDAQ:OTLK

Outlook Therapeutics Stock Forecast

etoro logo Buy OTLK
*Your capital is at risk
$1.15
+0.130 (+12.75%)
At Close: Aug 10, 2026

Should you buy OTLK stock?

Last updated:

Based on market data through , StockInvest.us rates Outlook Therapeutics Inc. (OTLK) as a Sell Candidate with a technical score of -1.36 on its -10 to +10 scale. The rating is unchanged from the previous daily evaluation.

  • Sell signal since
  • Price since signal Down 14.18%
  • 3-month trend forecast Up 71.93%
  • Sell Candidate -1.36
AI Analysis AI Analysis of OTLK AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add OTLK to Watchlist?
  • Easy Tracking In The Watchlist
PDF

Big movements in Outlook Therapeutics Inc. stock price on Monday moving 18.09% between high and low
(Market data through Aug 10, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Sell candidate since Jul 22, 2026 Loss -14.18%

The Outlook Therapeutics Inc. stock price gained 12.75% on the last trading day (Monday, 10th Aug 2026), rising from $1.02 to $1.15. During the last trading day the stock fluctuated 18.09% from a day low at $1.00 to a day high of $1.18. The price has risen in 6 of the last 10 days and is up by 7.98% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 6 million more shares were traded than the day before. In total, 10 million shares were bought and sold for approximately $11.70 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.99 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 71.93% during the next 3 months and, with a 90% probability hold a price between $1.71 and $4.08 at the end of this 3-month period.

OTLK Signals & Forecast

There are mixed signals in the stock today. The Outlook Therapeutics Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $1.38. On a fall, the stock will find some support from the short-term average at $1.00. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Monday, June 22, 2026, and so far it has fallen -37.16%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

Support, Risk & Stop-loss for Outlook Therapeutics Inc. stock

Outlook Therapeutics Inc. finds support from accumulated volume at $1.10 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.180 between high and low, or 18.09%. For the last week, the stock has had daily average volatility of 13.17%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (OTLK) For The Upcoming Trading Day Of Tuesday 11th

For the upcoming trading day on Tuesday, 11th we expect Outlook Therapeutics Inc. to open at $1.11, and during the day (based on 14 day Average True Range), to move between $1.07 and $1.23, which gives a possible trading interval of +/-$0.170 (+/-15.94%) up or down from last closing price. If Outlook Therapeutics Inc. takes out the full calculated possible swing range there will be an estimated 15.94% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $1.16 (0.87%) than the support at $1.10 (4.35%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Earnings coming up

Outlook Therapeutics Inc. will release earnings BMO on Thursday, August 13, 2026.The consensus among the analysts for the expected earnings (EPS) is -$0.0900. We will update the financials statements for Outlook Therapeutics Inc., that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 11.98% in the first trading day after earnings release.

Is Outlook Therapeutics Inc. stock A Buy?

Outlook Therapeutics Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.360 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on August 11, 2026 - $1.11 ( 3.77%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

OTLK Performance

Trading levels for OTLK

StockInvest.us
Full Access. No Commitment. Up to 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 1.29 11.88%
R2 1.22 5.90%
R1 1.18 2.21%
Price 1.15
S1 1.04 -9.75%
S2 1.00 -13.44%
S3 0.93 -19.42%

Accumulated Volume Support & Resistance Levels

Level Price
R3 1.41 22.17%
R2 1.22 6.09%
R1 1.16 0.87%
Price 1.15
S1 1.10 -4.35%
S2 1.07 -7.39%
S3 0.90 -21.39%

FAQ

What is the symbol for Outlook Therapeutics Inc. Stock and on which exchange is it traded?
The symbol for Outlook Therapeutics Inc. is OTLK and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Outlook Therapeutics Inc. Stock?
Based on market data through Aug 10, 2026, StockInvest.us rates Outlook Therapeutics Inc. (OTLK) as a Sell Candidate with a technical score of -1.36 on its -10 to +10 scale. The rating is unchanged from the previous daily evaluation. Since the Sell signal began on Jul 22, 2026, the price has fallen 14.18%. The current 3-month trend forecast projects a rise of 71.93%.

How to buy Outlook Therapeutics Inc. Stock?
Outlook Therapeutics Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Outlook Therapeutics Inc. Stock.

What's the current price of Outlook Therapeutics Inc. Stock?
As of the end of day on the Aug 10, 2026, the price of an Outlook Therapeutics Inc. (OTLK) share was $1.15.

What is the 52-week high and low for Outlook Therapeutics Inc. Stock?
The 52-week high for Outlook Therapeutics Inc. Stock is $3.39 and the 52-week low is $0.161.

What is the market capitalization of Outlook Therapeutics Inc. Stock?
As of the Aug 10, 2026, the market capitalization of Outlook Therapeutics Inc. is 138.993M.

When is the next earnings date for Outlook Therapeutics Inc.?
The upcoming earnings date for Outlook Therapeutics Inc. is Aug 13, 2026.
Click to get the best stock tips daily for free!
ABOUT OUTLOOK THERAPEUTICS INC.
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice...
GOLDEN STAR
Ticker Change Signal Date
GPOR
$158.45
6.03% Aug 06
FCX
$62.63
12.61% Jul 31
BIIB
$202.19
2.44% Jul 24
TSCO
$30.32
14.18% Jul 23
S
SW
$43.71
8.88% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE